Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ASH December 5 to 8

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Nov 26, 2020 7:46pm

318 Views

Post# 31986245

RE:RE:ASH December 5 to 8

Perhaps a miss-name of the event?
as ONC is clearly reporting as noted bellow:
:Not only are they presenting one-but 3 separate trial results.
That being the week of Dec 5-8th.perhaps being on the 9th confused people as not within the 5-8th week..lol

//stockhouse.com/news/press-releases/2020/11/17/oncolytics-biotech-xae-to-present-aware-1-data-and-provide-updates-on-phase-2

Sanantonio Brest Cancer Details on the abstracts and corresponding electronic posters are shown below. All posters will be available in a virtual poster hall beginning Wednesday, December 9, 2020 at 9:00 AM ET.

Poster Number: PS12-08
Title: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)
Session Name: Poster Session 12
Presenter: Dr. Luis Manso

Poster Number: OT-13-02
Title: Bracelet-1 (pre0113): a study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel
Session Name: Ongoing Trials Posters
Presenter: Dr. Kathy Miller

Poster Number: OT-32-02
Title: Irene study: phase 2 study of incmga00012 (retifanlimab) and the oncolytic virus pelareorep in metastatic triple negative breast cancer
Session Name: Ongoing Trials Posters
Presenter: Dr. Mridula George